Filing Analysis
Fractyl Health, Inc. announced its financial results for the quarter ended June 30, 2026, and provided a corporate update via an 8-K filing.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026
- Announcement date: August 10, 2026
- The company is classified as an emerging growth company.
Fractyl Health released one-year clinical data from its REMAIN-1 Midpoint Cohort regarding the Revita DMR System. The data suggests the device may help maintain weight loss after GLP-1 drug discontinuation, showing a 40% reduction in weight regain compared to a sham control.
🚩 Red Flags
- Clinical data is from a 'Midpoint Cohort,' meaning full pivotal results are still pending.
📋 Key Facts
- REMAIN-1 Midpoint Cohort (N=45) showed Revita reduced weight regain by ~40% vs. sham at one year (7.8% vs 13.0% body weight).
- Patients with complete duodenal ablation (>14 cm) maintained ~81% of GLP-1-induced weight loss, compared to 48% in the sham group.
- The responder rate for maintaining ≥5% total body weight loss was 73% in the full mITT population and 91% in the complete ablation subgroup.
- No device- or procedure-related serious adverse events (SAEs) were reported.
- TEAE rates were comparable between arms: 24% for Revita vs. 25% for sham.
Fractyl Health, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. The company successfully elected three Class II directors and ratified the appointment of Ernst & Young LLP as its independent auditor for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting held on June 10, 2026.
- Quorum achieved with 112,236,206 shares represented (approximately 70.7% of outstanding shares).
- Marc Elia, Clive Meanwell, and Ian Sheffield were elected as Class II directors for three-year terms.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Fractyl Health announced positive one-year results from its REVEAL-1 Cohort study, demonstrating that the Revita procedure helps patients maintain weight loss after discontinuing GLP-1 medications.
📋 Key Facts
- Patients maintained approximately 78% of their prior GLP-1-induced weight loss at one year post-Revita procedure.
- 33% of participants continued to lose weight one year after discontinuing GLP-1 therapy.
- 100% of patients in the cohort maintained at least 5% of their GLP-1-induced weight loss through one year.
- Mean total body weight change was 5.3% ± 2.1% (n=15) at one year.
- No procedure-related serious adverse events were reported; mild events occurred in 36% of participants within the first month.
Fractyl Health, Inc. (GUTS) furnished its financial results for the first quarter ended March 31, 2026, along with a corporate update. The filing is a routine quarterly disclosure and does not contain any immediate material changes to the company's structure or operations.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were announced on May 12, 2026.
- The company provided a corporate update alongside its financial performance.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Fractyl Health is an emerging growth company as defined by the SEC.
Fractyl Health announced it has received Clinical Trial Application (CTA) authorization in the Netherlands to initiate a Phase 1/2 first-in-human study of RJVA-001. This candidate is the first from the company's Rejuva Smart GLP-1 gene therapy platform to enter clinical testing.
📋 Key Facts
- Received CTA authorization in the Netherlands on May 11, 2026
- RJVA-001 is the first clinical candidate from the Rejuva Smart GLP-1 gene therapy platform
- The authorized study is a Phase 1/2 first-in-human clinical trial
- The announcement was made via a press release furnished under Item 7.01
Fractyl Health announced its Q4 and full-year 2025 financial results and provided a corporate update. The company also updated its corporate presentation to include new post hoc analyses from its REMAIN-1 clinical study.
📋 Key Facts
- Financial results for the quarter and full year ended December 31, 2025, were announced on March 24, 2026.
- Updated corporate presentation for use in meetings with investors and analysts.
- Provided new post hoc analyses for the REMAIN-1 Midpoint Cohort 6-month results.
- Analyses evaluated the relationship between treatment effect, procedural dose (length of duodenal ablation), and prior GLP-1-induced weight loss.
Fractyl Health, Inc. received a deficiency notice from Nasdaq on March 13, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has 180 days, until September 9, 2026, to regain compliance or face potential delisting.
🚩 Red Flags
- Minimum bid price deficiency (stock trading below $1.00).
- Explicit mention of a potential reverse stock split to cure the deficiency.
- Risk of delisting if compliance is not met within the 180-day grace period.
📋 Key Facts
- Notice received from Nasdaq on March 13, 2026, regarding non-compliance with Rule 5450(a)(1).
- Common stock bid price was below $1.00 for 30 consecutive business days.
- The compliance deadline is September 9, 2026.
- To regain compliance, the stock must close at $1.00 or higher for at least 10 consecutive business days.
- The company may transfer to the Nasdaq Capital Market or effect a reverse stock split to resolve the deficiency.
Fractyl Health announced the completion of participant randomization for its REMAIN-1 Pivotal Cohort, a study evaluating the Revita procedure for weight maintenance after GLP-1 therapy discontinuation. The company also provided updated 2026 clinical and regulatory milestones and reiterated its current cash guidance.
📋 Key Facts
- Completion of participant randomization in the REMAIN-1 Pivotal Cohort as of February 26, 2026.
- The REMAIN-1 study is a randomized, double-blind, sham-controlled trial.
- The study specifically targets weight maintenance in patients who have discontinued GLP-1 therapy.
- The company provided updated guidance on 2026 Revita clinical and regulatory milestones.
- Management reiterated previous cash guidance, suggesting no immediate change to their financial runway expectations.
Fractyl Health announced 6-month interim results from its REMAIN-1 Midpoint Cohort, demonstrating that the Revita DMR System may help maintain weight loss after GLP-1 discontinuation. The data showed a significant reduction in weight regain and improved cardiometabolic markers compared to a sham control.
🚩 Red Flags
- Midpoint cohort was not designed to be sufficiently powered for efficacy analysis (p-values provided as descriptive).
📋 Key Facts
- REMAIN-1 Midpoint Cohort 6-month data: Revita-treated patients saw 4.5% weight regain vs 7.5% in the sham arm (p=0.07).
- Exploratory analysis of high responders (above median GLP-1 loss) showed a 4.2% weight regain for Revita vs 13.3% for sham (p=0.004), a ~70% relative reduction.
- Cardiometabolic improvements: Increased HDL cholesterol (15.5 vs 3.9 mg/dL; p=0.01) and reduced triglyceride-to-HDL ratio in the Revita group.
- Safety profile remains favorable with no treatment-emergent serious adverse events related to the device or procedure reported through 6 months.
- The company is seeking FDA feedback on a De Novo pathway request for the Revita system, which could expedite regulatory review compared to the PMA pathway.
Fractyl Health announced a transition in its finance leadership, with Lisa Davidson resigning as CFO effective December 31, 2025, and Lara Smith Weber appointed to succeed her starting January 12, 2026. The filing includes details on the new CFO's compensation package and the separation/consulting agreements for the outgoing CFO.
🚩 Red Flags
- Executive turnover in a key financial role (CFO).
- Significant cash outflows related to the separation agreement ($630,000+).
📋 Key Facts
- Lisa Davidson resigned as CFO effective December 31, 2025; resignation is not due to any disagreement with management or the Board.
- Lara Smith Weber appointed as new CFO, effective January 12, 2026.
- New CFO Lara Smith Weber's compensation includes a $150,000 signing bonus and an option to purchase 1,036,800 shares of common stock.
- Outgoing CFO Lisa Davidson will receive separation benefits totaling approximately $630,000 ($450,000 base salary + $180,000 bonus) plus COBRA coverage and equity vesting.
- Ms. Davidson will provide consulting services at an hourly rate of $400 for up to three months following her departure.
Fractyl Health, Inc. provided a strategic update regarding its 2026 clinical/regulatory milestones for the Revita and Rejuva programs and updated its cash position. The company reported approximately $85.6 million in cash as of January 2, 2026.
🚩 Red Flags
- The company is still in a pre-revenue/clinical stage with significant upcoming clinical milestones that carry inherent failure risks.
📋 Key Facts
- Preliminary unaudited cash and cash equivalents as of Dec 31, 2025: ~$81.5 million.
- Cash balance increased to $85.6 million on Jan 2, 2026, following $4.1 million in Tranche A warrant exercises.
- Current cash runway is expected to fund operations through early 2027.
- Revita program milestones include potential PMA filing in H2 2026 and various clinical data readouts throughout the year.
- Rejuva program aims for first-in-human (FIH) dosing of RJVA-001 in H2 2026, subject to regulatory authorization.
Fractyl Health has issued a call notice to holders of its Tranche A Common Stock Purchase Warrants, stating that performance targets have been met. Holders can either accept a nominal cancellation fee or exercise the warrants at $1.05 per share before December 30, 2025.
🚩 Red Flags
- Potential for significant dilution if a large portion of the 17M+ warrants are exercised at $1.05 per share.
- The company is forcing action on warrants via a 'call' mechanism to prevent long-term overhang or to force conversion.
📋 Key Facts
- Company has achieved performance targets to call Tranche A Warrants for cancellation as of Dec 15, 2025.
- Tranche A Warrants consist of 17,063,073 outstanding warrants.
- Warrant holders may exercise at $1.05 per share or accept a $0.00001 cancellation fee.
- The call was triggered by clinical data from the REMAIN-1 study and stock price/volume performance (VWAP > $1.37 for 15 days; daily volume > $2M).
- Cancellation Date is set for December 30, 2025.
- The last reported share price was $2.24 on Dec 15, 2025.
Fractyl Health announced positive 6-month data from its open-label REVEAL-1 Cohort, suggesting the Revita procedure may help stabilize weight and HbA1c levels following GLP-1 discontinuation. The company also provided a roadmap for upcoming clinical readouts through 2026.
🚩 Red Flags
- Forward-looking statements explicitly mention the risk of significant net losses and the need for substantial additional financing.
- Explicitly mentions the 'ability to continue as a going concern' as a risk factor in the forward-looking statement disclaimer.
📋 Key Facts
- REVEAL-1 Cohort 6-month data: 17 participants showed mean total body weight change of 1.5% ± 1.3%.
- HbA1c levels remained stable with a minimal change of 0.04% ± 0.08%.
- No procedure-related serious adverse events were observed; 36% of participants experienced mild, transient adverse events.
- Upcoming Milestone: January 2026 - 6-month randomized data from REMAIN-1 Midpoint Cohort.
- Upcoming Milestone: H2 2026 - Potential Revita PMA filing for post-GLP-1 weight maintenance.
Fractyl Health, Inc. announced its financial results for the quarter ended September 30, 2025, and provided a corporate update via an 8-K filing on November 12, 2025.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025
- Filing date: November 12, 2025
- The company provided a corporate update alongside financial results
- Information under Item 2.02 is furnished but not filed for purposes of Section 18 liability
Fractyl Health, Inc. held a Special Meeting of Stockholders on October 3, 2025, where shareholders approved the issuance of common stock related to previously sold warrants. The meeting also approved an adjournment provision to solicit further proxies if necessary.
🚩 Red Flags
- The issuance is tied to warrants from a financing transaction closed on August 7, 2025, indicating recent capital needs or dilution events.
📋 Key Facts
- Special Meeting held on October 3, 2025.
- Quorum represented 64.12% of voting power (32,249,473 shares out of 50,289,014 outstanding).
- Proposal 1: Approval of share issuance pursuant to Nasdaq Listing Rule 5635(d) related to warrants from an August 7, 2025 financing.
- Proposal 1 Result: Approved (31,735,506 votes in favor).
- Proposal 2: Approval of meeting adjournment to solicit additional proxies. Result: Approved (31,744,878 votes in favor).
Fractyl Health, Inc. entered into an underwriting agreement to conduct a public offering of 60 million shares of common stock at $1.00 per share. The company expects net proceeds of approximately $56 million to extend its cash runway into early 2027.
🚩 Red Flags
- Significant dilution: Issuing 60 million shares at a low price point ($1.00) represents substantial dilution to existing shareholders.
- Capital raise necessity: The need to raise $56M to reach early 2027 indicates current cash burn is high.
📋 Key Facts
- Offering size: 60,000,000 shares of common stock.
- Offering price: $1.00 per share (less discounts and commissions).
- Estimated net proceeds: Approximately $56 million.
- Underwriters: BofA Securities, Inc. and Evercore Group L.L.C.
- Expected closing date: September 29, 2025.
- Use of proceeds: To fund operating expenses and capital expenditures through early 2027.
Fractyl Health reported positive 3-month interim data from its REMAIN-1 Midpoint Cohort, demonstrating that the Revita DMR System can facilitate additional weight loss even after GLP-1 discontinuation. The results showed a statistically significant difference in weight maintenance compared to a sham control group.
🚩 Red Flags
- Company explicitly mentions 'the fact that we expect to continue to incur significant net losses for the foreseeable future.'
- The company notes 'the need for substantial additional financing' and 'the ability to continue as a going concern' in its cautionary language.
📋 Key Facts
- REMAIN-1 Midpoint Cohort (45 participants) evaluated Revita's ability to maintain weight loss after stopping tirzepatide.
- Revita-treated patients achieved an additional 2.5% total body weight loss at 3 months post-tirzepatide discontinuation.
- Sham-treated patients experienced a 10% weight regain (p=0.014).
- No Revita-related Serious Adverse Events (SAEs) or Grade II+ Adverse Events (AEs) were observed through the 3-month mark.
- The company anticipates 6-month topline primary endpoint data from the Pivotal Cohort in early 2026 and a potential PMA filing in H2 2026.
Fractyl Health, Inc. announced the appointment of two new directors, Christopher Thompson, M.D. and Ian Sheffield, effective September 2, 2025. Additionally, Amy W. Schulman resigned from her position as a Class I director and member of the Nominating and Corporate Governance Committee.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Christopher Thompson, M.D. appointed as Class I director; term expires at 2028 annual meeting.
- Ian Sheffield appointed as Class II director and Audit Committee member; term expires at 2026 annual meeting.
- New directors to receive $43,500 annual retainer each; Mr. Sheffield receives an additional $10,000 for Audit Committee service.
- Both new directors granted options to purchase 45,000 shares of common stock, vesting over three years.
- Amy W. Schulman resigned as Class I director and member of the Nominating and Corporate Governance Committee, effective September 2, 2025.
- Company stated Ms. Schulman's resignation was not due to any dispute or disagreement regarding operations, policies, or practices.
Fractyl Health, Inc. announced its financial results for the quarter ended June 30, 2025, and provided a corporate update via an 8-K filing.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025.
- Announcement date: August 12, 2025.
- The filing includes a press release (Exhibit 99.1) containing financial results and a corporate update.
Fractyl Health, Inc. completed a significant underwritten public offering of common stock and warrants on August 7, 2025, raising approximately $20.7 million in net proceeds. The offering includes complex warrant structures (Tranche A and Tranche B) that require stockholder approval for the latter.
🚩 Red Flags
- Significant dilution potential: Warrants could yield up to an additional $46 million in future gross proceeds if fully exercised.
- Going concern risk mentioned in forward-looking statements regarding the need for substantial additional financing.
- Complex warrant structures (Tranche A/B) often lead to significant share overhang and volatility.
- Requirement of a special meeting to obtain stockholder approval for Tranche B Warrants.
📋 Key Facts
- Offered 19,047,619 shares of common stock at a combined price of $1.05 per share (including warrants).
- Underwriter Ladenburg Thalmann & Co. Inc. exercised its full option to purchase an additional 2,857,142 shares and associated warrants.
- Net proceeds from the offering totaled approximately $20.7 million.
- Tranche A Warrants: Exercise price of $1.05; exercisable on or after August 7, 2025; expire August 7, 2027.
- Tranche B Warrants: Exercise price of $1.05; require stockholder approval for exercise; expire 5 years from approval date.
- The company entered into a Voting Agreement with directors, officers, and Mithril LP to support the Tranche B Warrant Stockholder Proposal.
- Proceeds are earmarked for Revita and Rejuva pipeline programs and working capital.
Fractyl Health announced positive 3-month data from its REMAIN-1 pivotal study cohort, showing weight stability in participants after GLP-1 discontinuation. Additionally, the company presented preclinical data for its Rejuva® gene therapy platform and provided updated timelines for upcoming clinical readouts.
🚩 Red Flags
- Forward-looking statements acknowledge the company expects to continue to incur significant net losses for the foreseeable future.
- The company explicitly mentions the need for substantial additional financing and the ability to continue as a going concern in its risk disclosures.
📋 Key Facts
- REVEAL-1 cohort (REMAIN-1 study) 3-month data: 12 of 13 participants maintained or lost weight after GLP-1 discontinuation.
- Median weight remained stable through 3 months, avoiding the typical 5-6% rebound seen in other clinical studies.
- No unanticipated or serious adverse effects were observed during the procedure.
- REMAIN-1 Midpoint Cohort data is expected in Q3 2025; 6-month primary endpoint data for REMAIN-1 Pivotal Cohort expected H2 2026.
- Preclinical Rejuva® Smart GLP-1™ platform data showed a single dose prevented obesity and hyperglycemia in animal models.
- RJVA-001 (first clinical candidate) preliminary clinical data is anticipated in 2026.
Fractyl Health, Inc. announced the issuance of two new U.S. patents related to its duodenal resurfacing technology. The patents cover electrical energy ablation systems and methods for tissue treatment.
📋 Key Facts
- Issued U.S. Patent No. 12,329,439 on June 17, 2025.
- Issued U.S. Patent No. 12,303,185 on May 20, 2025.
- Patents focus on 'Electrical energy ablation systems, devices and methods for the treatment of tissue'.
- Technology involves ablating duodenal mucosa using thermal and non-thermal electrical energy.
Fractyl Health, Inc. held its Annual Meeting of Stockholders on June 11, 2025. The company successfully elected three Class I directors and ratified the appointment of Ernst & Young LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on June 11, 2025.
- Voting power represented: 34,467,774 shares (approx. 70.38% of outstanding common stock).
- William W. Bradley, Ajay Royan, and Amy W. Schulman were elected to the Board as Class I directors for three-year terms ending in 2028.
- Ernst & Young LLP was ratified as independent auditors for the fiscal year ending December 31, 2025.
Fractyl Health, Inc. announced the submission of the first module of its Clinical Trial Application (CTA) in Europe for RJVA-001, a gene therapy candidate from its Rejuva platform.
📋 Key Facts
- Submitted the first module of the CTA in Europe for RJVA-001 on May 19, 2025.
- RJVA-001 is part of the company's 'Rejuva' platform.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
Fractyl Health announced new preclinical data for its Rejuva smart GLP-1 gene therapy platform at the ASGCT 2025 Annual Meeting. The company is advancing toward first-in-human studies, with a Clinical Trial Application (CTA) module submission expected by June 2025.
🚩 Red Flags
- Forward-looking statements include risks regarding significant net losses and the need for substantial additional financing.
- Explicit mention of uncertainty regarding the ability to continue as a going concern in the risk disclosures.
📋 Key Facts
- Presented preclinical data for RJVA-001 at the ASGCT 2025 Annual Meeting in New Orleans.
- RJVA-001 aims to deliver durable, nutrient-responsive GLP-1 secretion from pancreatic beta cells.
- Preclinical data showed strong efficacy, targeted delivery, and a favorable safety profile.
- First Clinical Trial Application (CTA) module submission for RJVA-001 is expected by June 2025.
Fractyl Health, Inc. announced its financial results for the fiscal quarter ended March 31, 2025, and provided a corporate update via an 8-K filing.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Announcement date: May 13, 2025
- The company is classified as an emerging growth company.
- Financial results and corporate update were released via press release (Exhibit 99.1).
Fractyl Health announced positive early data from the REVEAL-1 cohort of its REMAIN-1 pivotal study, showing evidence of weight maintenance after GLP-1 discontinuation. The company also provided updates on enrollment progress and upcoming clinical milestones.
📋 Key Facts
- Early data from the open-label REVEAL-1 cohort (first seven patients) shows evidence of weight maintenance following GLP-1 discontinuation.
- The REMAIN-1 pivotal study is more than 50% enrolled.
- Full enrollment for the REMAIN-1 study is anticipated in Summer 2025.
- A mid-point analysis from the REMAIN-1 study is expected in Q3 2025.
Fractyl Health, Inc. announced the scheduling of its 2025 Annual Meeting of Stockholders for June 11, 2025. The filing also outlines specific deadlines for stockholder proposals and director nominations to be included in the upcoming proxy materials.
🚩 Red Flags
- The company did not hold an annual meeting in 2024, which may indicate previous administrative or governance irregularities/delays.
📋 Key Facts
- The 2025 Annual Meeting of Stockholders is scheduled for June 11, 2025.
- Stockholder proposals must be received by March 23, 2025, to be considered for inclusion in proxy materials under Rule 14a-8.
- Written notice of any proposed business or director nominations must be received by the company no later than March 23, 2025.
- The Company did not hold an annual meeting in 2024.
Fractyl Health, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024, alongside a corporate update.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2024
- Announcement date: March 3, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an emerging growth company
Fractyl Health is implementing a strategic reprioritization to focus on its lead product candidate (Revita) and gene therapy platform (Rejuva), while pausing other programs. This restructuring includes a 17% workforce reduction and an estimated $1.8 million in severance costs.
🚩 Red Flags
- Workforce reduction (17% of staff) indicates significant cost-cutting measures.
- Uncertainty regarding additional costs related to contract terminations.
- Forward-looking statements explicitly mention the 'ability to continue as a going concern' and the need for 'substantial additional financing'.
📋 Key Facts
- Strategic reprioritization approved on January 31, 2025.
- Prioritizing REMAIN-1 pivotal study for Revita (weight maintenance after tirzepatide).
- Advancing Rejuva gene therapy platform into first-in-human studies.
- Pausing investment in type 2 diabetes programs (REVITALIZE-1 and German Real-World Registry).
- Workforce reduction of 22 employees, representing approximately 17% of the total workforce.
- Estimated cash charges of $1.8 million for severance and benefits; additional contract termination costs are being assessed.
- Management believes current cash/equivalents are sufficient to fund operations into 2026.
Fractyl Health issued a press release under Item 7.01 regarding preliminary clinical data and study enrollment updates. The company reported weight maintenance results in the first patient of the REVEAL-1 cohort following GLP-1 discontinuation.
🚩 Red Flags
- Clinical data delays: REVEAL-1 cohort data was 'delayed slightly due to holiday related scheduling issues'.
📋 Key Facts
- Preliminary results from the REVEAL-1 cohort show weight maintenance in the first patient after GLP-1 drug discontinuation and Revita procedure.
- Full data from the REVEAL-1 cohort is expected to be presented in Q1 2025.
- REMAIN-1 pivotal study enrollment is progressing strongly.
- Mid-point analysis for the REMAIN-1 study is on track for Q2 2025.
Fractyl Health, Inc. announced its financial results for the quarter ended September 30, 2024, along with a corporate update via a press release.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024
- Announcement date: November 12, 2024
- The filing includes an announcement of financial results and a corporate update.
Fractyl Health announced the nomination of RJVA-002, a GIP/GLP-1 pancreatic gene therapy lead candidate for obesity treatment. The company also plans to present preclinical data regarding its Rejuva RJV-001 candidate at an upcoming industry conference.
📋 Key Facts
- Nominated RJVA-002 as first GIP/GLP-1 pancreatic gene therapy lead candidate for obesity.
- RJVA-002 utilizes a locally administered AAV9 viral vector expressing human GIP and GLP-1 hormones.
- Scheduled to present preclinical data on sustained weight maintenance for RJV-001 at The Obesity Society’s Annual Meeting (ObesityWeek 2024) on November 5, 2024.
Fractyl Health, Inc. announced its financial results for the quarter ended June 30, 2024, and provided a corporate update via an 8-K filing on August 14, 2024.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Filing date: August 14, 2024
- The company provided a corporate update alongside financial results
- Information under Item 2.02 is furnished but not filed for purposes of Section 18 liability
Fractyl Health announced that the FDA has granted Breakthrough Device Designation for its Revita System to assist in weight loss maintenance following GLP-1 drug discontinuation. The company also noted that its REMAIN-1 pivotal study is currently underway with data readouts expected starting in Q4 2024.
📋 Key Facts
- FDA granted Breakthrough Device Designation for the Revita System.
- The device is intended for use in maintaining weight loss after discontinuation of GLP-1 drugs.
- The REMAIN-1 pivotal study is currently underway.
- Anticipated data readouts from the REMAIN-1 study are expected to begin in Q4 2024.
Fractyl Health, Inc. issued a press release providing corporate updates regarding clinical studies for its Revita® products (REMAIN-1, REVEAL-1, and REVITALIZE-1) and updated its investor relations slide presentation.
📋 Key Facts
- Issued a press release on June 24, 2024, containing corporate updates.
- Updates include clinical study information for Revita® weight maintenance (REMAIN-1 and REVEAL-1 cohorts) and Revita type 2 diabetes (REVITALIZE-1).
- Updated the corporate slide presentation on the company's investor relations website.
Fractyl Health, Inc. announced its financial results for the fiscal quarter ended March 31, 2024, and provided a corporate update via an 8-K filing.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Announcement date: May 13, 2024
- The filing includes results of operations and financial condition under Item 2.02
- A press release was furnished as Exhibit 99.1
Fractyl Health announced that it has received an Investigational Device Exemption (IDE) from the FDA to study the efficacy of its Revita device in maintaining weight loss after discontinuing GLP-1 receptor agonist therapy. The company also updated its corporate slide presentation on its investor relations website.
📋 Key Facts
- Received FDA Investigational Device Exemption (IDE) for Revita device.
- Study focus: Efficacy of Revita in maintaining weight loss following discontinuation of GLP-1RA drug therapy.
- Updated corporate slide presentation released on investor relations website as of April 1, 2024.
Fractyl Health, Inc. filed an 8-K to announce its financial results for the quarter and year ended December 31, 2023, alongside a corporate update.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2023.
- Announcement date: April 1, 2024.
- The filing includes an earnings press release as Exhibit 99.1.
Fractyl Health, Inc. completed its initial public offering (IPO) of 7,333,333 shares at $15.00 per share, raising approximately $110 million in gross proceeds. The filing also details amendments to the company's Certificate of Incorporation and Bylaws effective upon the closing of the IPO.
🚩 Red Flags
- Implementation of 'poison pill' style protections: requires 2/3 vote to remove directors or amend bylaws, making hostile takeovers difficult.
- Elimination of stockholder ability to act via written consent.
📋 Key Facts
- Completed IPO of 7,333,333 shares of common stock.
- Offering price: $15.00 per share.
- Gross proceeds: Approximately $110 million (before underwriting discounts and expenses).
- Amended Certificate of Incorporation authorizes 300,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock.
- Established a classified board of directors.
- Implemented provisions prohibiting stockholder action by written consent and requiring two-thirds majority for director removal or bylaw amendments.